Post-Op Complication
Conditions
Brief summary
The aim of this study was to assess the effect of intrathecally injected 5 µg dexmedetomidine or 25 µg fentanyl as adjuvants to bupivacaine in low dose spinal anesthesia for unilateral arthroscopic knee surgeries, on post-operative urinary retention (POUR), time needed to reach sensory block at the tenth thoracic dermatome (T10), the maximum sensory level achieved, the onset of motor block, the intra-operative fluids given, the duration of sensory and motor blocks, time to micturition or insertion of an intermittent urinary catheter and the number of patients who needed an indwelling (Foley's) catheter. Seventy patients, ASA physical status I or II, from 21 to 50 years old, scheduled to undergo unilateral arthroscopic knee surgeries under spinal anesthesia, were randomly divided into two equal groups; the Bupivacaine- Dexmedetomidine group (BD) patients and the Bupivacaine-Fentanyl group (BF) patients.
Interventions
In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
DRUGBupivacaine-Fentanyl group
In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* ASA physical status I and II * aged 21-50 years * scheduled to undergo unilateral arthroscopic knee surgeries under spinal anesthesia
Exclusion criteria
* Patients' refusal * contraindications to spinal anesthesia * patients with coagulopathy * infection at the lumbar region * pre-existing neurological deficits in the lower limbs * known allergy to any of the study drugs * urinary incontinence * cysto-ureteric reflux * patients with congestive heart failure * patients with dysrhythmia * patients with heart block * diabetic patients * patients on α2-adrenergic receptors antagonists * calcium channel blockers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-operative urinary retention | 3 hours | Ultrasound assessment of the urinary bladder volume was done at the 3rd post-operative hour, a bladder volume of \>700 ml with no ability to void confirmed the presence of urinary retention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum sensory level achieved | 30 minutes | Sensory level assessment by loss of sensation to pinprick every 2 minutes, until the highest level had stabilized for four consecutive tests |
| The onset of motor block | 30 minutes | The time from completion of intrathecal injection of the study drug till having a modified Bromage score = 1 or more |
| Intra-operative fluids given | 3 hours | The volume of IV Ringer's solution given to each patient according to the fluid chart |
| Time to reach sensory block at T10 | 30 minutes | The time from completion of intrathecal injection of the study drug till loss of sensation to pin prick at T10 on the operative side, assessed every 2 minutes. |
| Duration of motor block | 6 hours | The time from completion of intrathecal injection of the study drug till complete recovery of the motor function (MBS = 0), by asking the patient to flex the hip, knee and ankle joints, in the PACU, then every 15 minutes in the ward |
| Time to micturition or insertion of an intermittent urinary catheter | 6 hours | The time from completion of intrathecal injection of the study drug till voiding or insertion of an in-out catheter |
| Number of patients who needed an indwelling (Foley's) catheter | 6 hours | After 6 post-operative hours, if the patient wasn't able to void an indwelling (Foley's) catheter was then placed |
| Duration of sensory block | 6 hours | he time from completion of intrathecal injection of the study drug till regression to the third sacral dermatome (S3) level |
Countries
Egypt
Outcome results
None listed